Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Citius Pharmaceuticals (CTXR – Research Report), Arcus Biosciences (RCUS – Research Report) and Masimo (MASI – Research Report).
Citius Pharmaceuticals (CTXR)
H.C. Wainwright analyst Vernon Bernardino reiterated a Buy rating on Citius Pharmaceuticals on January 16 and set a price target of $4.00. The company’s shares closed last Monday at $0.70, close to its 52-week low of $0.60.
According to TipRanks.com, Bernardino is a 4-star analyst with an average return of
Citius Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $4.00, which is a 455.6% upside from current levels. In a report issued on January 2, Maxim Group also maintained a Buy rating on the stock with a $4.00 price target.
See the top stocks recommended by analysts >>
Arcus Biosciences (RCUS)
In a report issued on January 19, Peter Lawson from Barclays assigned a Buy rating to Arcus Biosciences, with a price target of $35.00. The company’s shares closed last Monday at $15.11.
According to TipRanks.com, Lawson is a 4-star analyst with an average return of
Currently, the analyst consensus on Arcus Biosciences is a Strong Buy with an average price target of $42.86, representing a 178.9% upside. In a report issued on January 16, Mizuho Securities also assigned a Buy rating to the stock with a $51.00 price target.
Masimo (MASI)
Needham analyst Michael Matson maintained a Hold rating on Masimo on January 16. The company’s shares closed last Monday at $125.57.
According to TipRanks.com, Matson is a 1-star analyst with an average return of
Masimo has an analyst consensus of Moderate Buy, with a price target consensus of $108.80, implying a -14.0% downside from current levels. In a report issued on January 10, Stifel Nicolaus also maintained a Hold rating on the stock with a $125.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on CTXR:
